2022 Program Plans
Our initiatives will focus on transforming the future of liver disease by sharing best practices and driving implementation of knowledge. Key themes will be optimizing the relationships with patients and providers. We do this through the understanding of new medical innovations, the patient experience, drive understanding and awareness through the healthcare team, and the collection and analysis of patient-centered information.
The mission of the CLA through these initiatives is to unite patients, providers and the health industry to deliver the best possible care and develop new, scalable solutions for the fight against liver disease.
2022 program goals include:
- Collect, summarize and transparently share data for better outcomes in liver disease prevention and treatment.
- Develop educational materials for both the patient and the provider.
- Develop collaborative projects to address gaps in liver disease awareness, screening, intervention, diagnosis, referral and treatment .
- Raise much needed funds and awareness through our annual fundraising events to support patient assistance programs, research and advocacy efforts.
APPALACHIA VIRAL HEPATITIS ELIMINATION SUMMIT
The first central Appalachian hepatitis C elimination summit will be held in the fall of 2021 with a focus on eliminating viral hepatitis C in people who use drugs. Plan by key stakeholders representing central Appalachian states, including those with lived experience, the summit will allow for learning, networking and collaboration through sessions to talk about expanding the role of harm reduction in preventing hepatitis C infections and increasing access to hepatitis C testing and treatment in high-risk populations.
LIVER JOURNAL CLUB
Our new Liver Journal Club series will be held each quarter. Topics include HCC/PBC, Fatty Liver/NASH, Viral Hepatitis, Cirrhosis and other liver conditions. Presentations are given by medical fellows to an audience of their peers and other health providers to critically evaluate recent articles in the academic literature.
Clinical Trials Educational Video
The NASH Update is an annual interactive conference directed at the patient and caregiver. Content includes education about screening recommendations, lifestyle modification, current treatment options, drug trials, pediatric diseases, healthy cooking and physical activity demonstrations. A concurrent provider CME session educates hepatologists, gastroenterologists, primary care physicians and other health care providers involved in the management of patients with liver disease about NASH/NAFLD, both pharmacologic and endoscopic, emerging nutritional and weight management research related to NASH/NAFLD, extra-hepatic manifestations associated with NASH, management options and screening options.
Developed in conjunction with PBC patients, this educational program will include up-to-date information about PBC treatments, developments, clinical trials, transplantation, nutrition, resources, support, and more. The goal of PBC Update is to educate, connect, and support patients, caregivers, and providers in an open, informative setting through concurrent patient and provider sessions.
Liver Cancer Roundtable
Pediatric Liver Disease Conference
The Pediatric Liver Conference brings together small case Pediatric Liver Specialist and caregivers that are managing a child with liver disease or transplant. The conference will focus on recent advances in the diagnosis and management of children with a wide variety of liver diseases. We will also hear from other caregivers who have firsthand knowledge on how to care for a child with liver disease. There will be Q&A to help even the newest parent navigate the ins and outs of caring for your child.
PBC SUPPORT GROUP MEETINGS
Support Group Meetings
Alcoholic Liver Disease Symposium
Clinical Trials Provider Video
Disparities in Liver Diseases
The HCV Roundtable Discussion Series is designed to support the providers who participated in the CLA HCV Treatment Training. The sessions offer an opportunity for participants to convene in an informal setting with subject matter experts to examine their HCV patient cases and to share information and feedback with each other.
HCV Speaker Series
The CLA HCV Speaker Series is an opportunity for anyone currently treating patients with HCV to be educated by subject matter experts on specific topics which may include, addressing reinfection, screening and treating pregnant women, monitoring and treating children, and novel approaches to screening and treatment in a rural setting. We will also provide a post-program evaluation to gather feedback on additional topics of interest.
Hepatitis C Learning Lab
The overarching goal of this project is to advance hepatitis C prevention for people who inject drugs by supporting harm reduction services, advocacy, and education across West Virginia, Tennessee, North Carolina, Indiana, and Kentucky through grant making and technical assistance. The Learning Lab Program will engage HEP Connect Grantees with experiential learning and mentorship by subject matter experts. This program, which will focus on 5 core competencies;(Communication, Leadership, Business Basics, Building Relationships, and Personal Branding) will have as its end goal, the expansion of harm reduction services to persons who use drugs (PWUD). Our aim is to instill new proficiencies to enhance their existing skills and knowledge. Investing in individual development will inspire racial equity, and justice by bringing down silos and biases through better interactions with diverse audiences and individuals. The program will be developed by people with lived experience and other subject matter experts to ensure we achieve the best possible outcomes and to collect data for analysis, reporting and program improvement.
Hepatitis C Provider Network
In collaboration with the National Harm Reduction Coalition, the CLA convenes monthly virtual HCV Provider Networking meetings with enduring education, networking and actionable information. The HCV Provider Network reaches clinicians to educate on the importance of harm reduction services and as it relates to hepatitis C prevention and actively engages them to become advocates to inspire change. Members of the HCV Provider Network serve on the central Appalachia Viral Hepatitis Elimination Summit planning committee. HCV Provider Network members will also serve as mentors, educators and planning committee members for the Learning Lab Program. The HCV Provider Network will actively advocate to expand harm reduction services within their communities through education, activism and support. The Network will offer expert testimony to bring down statutory barriers, provide trainings and education to preserve harm reduction services, access to hepatitis C screening, treatment and linkage to care.
Hepatitis D Education Program
The CLA hepatitis D Patient and Provider Education Program would be a pilot program focused on the Asian &Pacific Islander population as it relates to Hepatitis B and D. Through education outreach in these communities we would raise awareness to screening and treatment of not only this vulnerable population but also the health care providers who treat them. Our goals of the program are:
- Provide information/education to patients and providers.
- Develop a guide for screening for providers.
- Create a Hep D webpage for resources.
Digital downloads available as resources.
- Provider information to give to patients.
Conduct focus population screening activities.
- Outreach to community centers, Asian-American churches, Asian-American radio, APAMSA, Asian-American minority owned business and associations for collaborations.
- Translated materials into Hmong (Asian), Vietnamese and other Asian languages.
Liver Cancer Conference
The goal of the Liver Cancer Conference is to help clinicians and other service providers understand the management of Hepatocellular Carcinoma in the US population, innovations in therapies, and advances in research and development. This program is directed to providers, patients and caregivers. Concurrent educational sessions will be held for hepatologists, gastroenterologists, oncologists, primary care physicians and other health care providers involved in the management of patients with liver cancer. A separate session will be geared towards patients and their caregivers.
Post AASLD Provider Conference
The goal of the CME program is to bring the key findings of the 2021 AASLD National Conference to the broader liver community to learn about current trends, management techniques, recent innovations, and research to treat a full range of liver conditions, including Fatty Liver/NASH, Hepatocellular Carcinoma, Cholestatic Diseases, Pediatric Liver Diseases and Liver Transplantation.
Rare Liver Disease Conference
This program is another opportunity for the Community Liver Alliance to help clinicians, service providers, patients and their caregivers to understand the more rare diseases that affect the liver including Autoimmune Hepatitis, PBC, PSC and pediatric liver disease. The program will educate both clinicians and patients on these diseases, current and pipeline therapies, resources, and provide networking opportunities with the region's liver experts through concurrent patient and provider sessions.
The Transplant Update features world-class speakers providing cutting-edge research and clinical information in transplant medicine. Information is provided to both clinicians and caregivers in separate, concurrent sessions.
Treating HCV in a Primary Care Setting
The NASH Update is an annual interactive conference directed at the patient and caregiver. Content includes education about screening recommendations, lifestyle modification, current treatment options, drug trials, pediatric diseases, healthy cooking and physical activity demonstrations. A concurrent provider CME session educates hepatologists, gastroenterologists, primary care physicians and other healthcare providers involved in the management of patients with liver disease about NASH/NAFLD, both pharmacologic and endoscopic, emerging nutritional and weight management research related to NASH/NAFLD, extra-hepatic manifestations associated with NASH, management options and screening options.